✦ LIBER ✦

1200 POSTER Phase II study of thalidomide in patients with brain metastases from malignant melanoma

Book ID: 123268187
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 143 KB
Volume: 3
Category: Article
ISSN: 1359-6349
DOI: 10.1016/S1359-6349(05)81494-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Temozolomide plus thalidomide in patient

Temozolomide plus thalidomide in patients with brain metastases from melanoma : A Phase II study

✍ Wen-Jen Hwu; Eric Lis; Jennifer H. Menell; Katherine S. Panageas; Lynne A. Lamb; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB

## Abstract ## BACKGROUND Temozolomide plus thalidomide is a promising oral combination regimen for the treatment of metastatic melanoma. The current Phase II study examined the efficacy and safety of this combination in chemotherapy‐naive patients with brain metastases. ## METHODS Patients with

Value of radiation therapy in the manage

Value of radiation therapy in the management of patients with cerebral metastases from malignant melanoma: R.T.O.G. brain metastases phases I & II

✍ Richard J. Carella; Richard Gelber; Frank Hendrickson; Herbert C. Berry; Jay S. 📂 Article 📅 1978 🏛 Elsevier Science 🌐 English ⚖ 70 KB

Demographics, prognosis, and therapy in

Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma

✍ Sampson, John H.; Carter, James H.; Friedman, Allan H.; Seigler, Hilliard F. 📂 Article 📅 1998 🏛 American Association of Neurological Surgeons 🌐 English ⚖ 283 KB

A phase II study of spirogermanium in pa

A phase II study of spirogermanium in patients with metastatic malignant melanoma

✍ Elizabeth Eisenhauer; Ian Kerr; Audley Bodurtha; Neill Iscoe; Peter McCulloch; K 📂 Article 📅 1985 🏛 Springer US 🌐 English ⚖ 205 KB

The National Cancer Institute of Canada Clinical Trials Group conducted a phase II study of spirogermanium given daily for 5 days every 3 weeks to previously untreated patients with malignant melanoma. In 21 evaluable patients one complete response was seen (response rate 5%). Disease progression oc

Temozolomide, thalidomide, and whole bra

Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma : A phase II Cytokine Working Group study

✍ Michael B. Atkins; Jeffrey A. Sosman; Sanjiv Agarwala; Theodore Logan; Joseph I. 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

Value of radiation therapy in the manage

Value of radiation therapy in the management of patients with cerebral metastases from malignant melanoma. Radiation therapy oncology group brain metastases study I and II

✍ Richard J. Carella; Richard Gelber; Frank Hendrickson; Herbert C. Berry; Jay S. 📂 Article 📅 1980 🏛 John Wiley and Sons 🌐 English ⚖ 357 KB 👁 2 views